NP5.F NEWRON PHARMACEUT. EO-20
- Market cap
- EUR 195M
- P/E
- -
- P/B
- 172.36x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is NP5.F undervalued?
Graham numberThe Graham number of NEWRON PHARMACEUT. EO-20 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NEWRON PHARMACEUT. EO-20 fundamental analysis
No fundamental analysis for NEWRON PHARMACEUT. EO-20 yet.
NEWRON PHARMACEUT. EO-20 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizo…
Full company profileNEWRON PHARMACEUT. EO-20 financial statements
NEWRON PHARMACEUT. EO-20 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.76M | 6.09M | 9.06M | 51.4M | 19.1M |
| Operating Income | -12.4M | -13.3M | -11.6M | 26.2M | -4.70M |
| EBITDA | - | -13.3M | -11.8M | 25.9M | -7.78M |
| Net Income | -14.9M | -17.5M | -16.2M | 15.8M | -13.2M |
| EPS | -0.84 | -0.98 | -0.91 | 0.79 | -0.66 |
| Balance Sheet | |||||
| Total Assets | 50.5M | 37.2M | 25.9M | 63.9M | 40.1M |
| Total Liabilities | 47.4M | 51.2M | 55.8M | 62.5M | 51.2M |
| Shareholders' Equity | 3.11M | -14.0M | -29.9M | 1.46M | -11.1M |
| Cash & Short-term Investments | 25.0M | 13.4M | 6.34M | 6.93M | 12.2M |
| Cash Flow | |||||
| Operating Cash Flow | -11.4M | -11.1M | -10.1M | -17.6M | 32.3M |
| Capital Expenditure | 20.0K | 18.0K | 11.0K | 13.0K | 48.0K |
| Free Cash Flow | -11.5M | -11.1M | -10.2M | -17.6M | 32.3M |
| Ratios | |||||
| ROE | -479.6% | - | - | 1,086.6% | - |
| ROA | -29.5% | -47.0% | -62.7% | 24.8% | -33.1% |
| Net Profit Margin | -258.6% | -287.1% | -179.1% | 30.8% | -69.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NEWRON PHARMACEUT. EO-20 dividends
NEWRON PHARMACEUT. EO-20 has not paid dividends in the last 5 fiscal years.
Who owns NEWRON PHARMACEUT. EO-20
- Insiders 12.84%
- Institutions 12.45%
- Public & others 74.71%
- Shares outstanding 20.4M
- Free float 18.9M
NEWRON PHARMACEUT. EO-20 company profile
- Company name
- NEWRON PHARMACEUT. EO-20
- Ticker
- NP5.F
- ISIN
- IT0004147952
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- Via Antonio Meucci 3, Bresso, MI, Italy, 20091
- Phone
- 39 02 610 3461
- Website
- newron.com
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
NEWRON PHARMACEUT. EO-20 management
5- Mr. Stefan WeberCEO & Executive Director · born 1965
- Mr. Roberto GalliChief Financial Officer
- Mr. Filippo MoriggiaVice President of Operations
- Dr. Ravi Anand M.D., Ph.D.Chief Medical Officer · born 1957
- Ms. Laura FaravelliVice President of Business Development